脑出血急性期强化降压反应的地域差异
该研究为ATACH-2试验预设亚组分析,比较东亚与非亚洲脑出血患者强化降压对临床与血肿结局的影响。共纳入537例东亚和463例非亚洲患者,强化目标110-139 mmHg,标准目标140-179 mmHg。东亚患者90天不良功能结局、死亡及心肾不良事件均较少,仅东亚患者强化降压减少血肿扩大。
要点
- 东亚脑出血患者90天不良功能结局和死亡低于非亚洲患者
- 仅东亚队列强化降压显著降低24小时血肿扩大风险
- 两个队列强化降压均增加7天内心肾不良事件
核心结论
- 东亚脑出血患者90天不良功能结局和死亡较非亚洲患者少见,强化降压仅在该队列减少血肿扩大。
研究设计与样本
- ATACH-2随机、多国、两组、开放标签试验的预设亚组分析,共纳入537例东亚和463例非亚洲脑出血患者。
主要发现
- 东亚与非亚洲患者不良功能结局分别为32.0%与45.9%,死亡分别为1.9%与13.3%,心肾不良事件分别为3.9%与11.2%。
- 治疗与队列交互作用对所有结局均不显著。
- 仅东亚患者强化降压降低血肿扩大(校正相对风险0.56,95%CI 0.38-0.83)。
- 东亚(相对风险3.53,95%CI 1.28-9.64)与非亚洲(相对风险1.71,95%CI 1.00-2.93)队列强化降压均增加心肾不良事件。
关键数值与推荐
- 强化降压目标为收缩压110-139 mmHg,标准降压目标为140-179 mmHg。
临床怎么用
- 东亚脑出血患者急性期强化降压可能更多获益于减少血肿扩大,但需警惕心肾不良事件。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the impact of intensive blood pressure (BP) lowering right after intracerebral hemorrhage (ICH) on clinical and hematoma outcomes among patients from different geographic locations, we performed a prespecified subanalysis of a randomized, multinational, 2-group, open-label trial to determine the efficacy of rapidly lowering BP in hyperacute ICH (Antihypertensive Treatment of Acute Cerebral Hemorrhage [ATACH]-2), involving 537 patients from East Asia and 463 recruited outside of Asia. METHODS: Eligible patients were randomly assigned to a systolic BP target of 110 to 139 mm Hg (intensive treatment) or 140 to 179 mm Hg (standard treatment). Predefined outcomes were poor functional outcome (modified Rankin Scale score 4-6 at 90 days), death within 90 days, hematoma expansion at 24 hours, and cardiorenal adverse events within 7 days. RESULTS: Poor functional outcomes (32.0% vs 45.9%), death (1.9% vs 13.3%), and cardiorenal adverse events (3.9% vs 11.2%) occurred significantly less frequently in patients from Asia than those outside of Asia. The treatment-by-cohort interaction was not significant for any outcomes. Only patients from Asia showed a lower incidence of hematoma expansion with intensive treatment (adjusted relative risk [RR] 0.56, 95% confidence interval [CI] 0.38-0.83). Both Asian (RR 3.53, 95% CI 1.28-9.64) and non-Asian (RR 1.71, 95% CI 1.00-2.93) cohorts showed a higher incidence of cardiorenal adverse events with intensive treatment. CONCLUSIONS: Poor functional outcomes and death 90 days after ICH were less common in patients from East Asia than those outside of Asia. Hematoma expansion, a potential predictor for poor clinical outcome, was attenuated by intensive BP lowering only in the Asian cohort. CLINICALTRIALSGOV IDENTIFIER: NCT01176565. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for patients from East Asia with ICH, intensive blood pressure lowering significantly reduces the risk of hematoma expansion.
引用
- Toyoda K, Palesch YY, Koga M, et al. Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage. Neurology. 2020. PMID: 33219136. doi:10.1212/WNL.0000000000011229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。